2-bromo-3-propoxypyridine | 461661-44-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-3-propoxypyridine
• CAS: 461661-44-9
• 化学式: C₈H₁₀BrNO
• 分子量: 216.077
• InChiKey: WKTVQPLAMOUHGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-溴-3-甲氧基-6-硝基吡啶 、 2-bromo-3-propoxypyridine 生成 2-bromo-6-nitro-3-propoxypyridine
  参考文献：
  名称：

  Triazole Compounds as Lipoxygenase Inhibitors

  摘要：

  提供了化合物的公式(I)，其中W是可选取代的芳基或杂环芳基基团，以及其药学上可接受的盐。这些化合物在治疗需要抑制脂氧合酶(例如15-脂氧合酶)活性的疾病中非常有用，特别是在治疗炎症方面。

  公开号：

  US20090186918A1
• 作为产物：
  描述：

  2-溴-3-乙氧基吡啶 、 2-溴-3-羟基吡啶 、 1-碘代丙烷 生成 2-bromo-3-propoxypyridine
  参考文献：
  名称：

  Pyrazoles Useful in the Treatment of Inflammation

  摘要：

  提供了公式（I）的化合物，其中R1、R2、X1、X2和n在说明中给出其含义，以及其药学上可接受的盐。这些化合物在治疗需要抑制脂氧合酶（例如15-脂氧合酶）活性的疾病，特别是在治疗炎症方面非常有用。

  公开号：

  US20090143440A1

文献信息

• BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1422228A1

  公开（公告）日：2004-05-26

  The present invention provides a novel benzazepine derivative represented by formula : wherein, R1 is a 5- or 6-membered aromatic ring, R2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula -W1-X2-W2- (W1 and W2 are independently S(O)m1 (m1 is 0, 1 or 2), etc., and X2 is an optionally substituted alkylene groupetc. ), a preparation method and use thereof.

  本发明提供了一种新型的苯并氮杂环衍生物，其由以下公式表示： 其中，R1是一个5-或6-成员的芳香环，R2是低级烷基团等，Y是可选地取代的亚氨基，环A和环B是独立地选自一个可选地取代的芳香环，W是公式-W1-X2-W2-（W1和W2是独立地为S(O)m1（m1是0、1或2）等，X2是一个可选地取代的亚烷基团等），其制备方法及其用途。
• [EN] BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5<br/>[FR] AMINES ET ETHERS DE BIPYRIDYLE UTILISES COMME MODULATEURS DU RECEPTEUR 5 METABOTROPIQUE AU GLUTAMATE
  申请人：MERCK & CO INC

  公开号：WO2005021529A1

  公开（公告）日：2005-03-10

  The present invention is directed to novel bipyridyl amine and ether compounds such as those of Formula (I): (I) (where R?1#191, R?2#191, R?3#191, X and Y are as defined herein) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel bipyridyl amine and/or ether compounds and/or compositions containing these compounds.

  本发明涉及一种新型的双吡啶基胺和醚化合物，例如式(I)中的化合物：（I）（其中R?1#191，R?2#191，R?3#191，X和Y的定义如本文所述），这些化合物是mGluR5调节剂，可用于治疗或预防涉及mGluR5的疾病和症状，包括但不限于精神和情绪障碍，如精神分裂症、焦虑、抑郁症、双相情感障碍和恐慌，以及用于疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍，如倒班工作引起的睡眠障碍和时差反应，药物成瘾、药物滥用、戒断综合征、肥胖症和其他疾病的治疗。本发明还涉及包含这些化合物的药物组合物。本发明还提供了一种通过给予这些新型双吡啶基胺和/或醚化合物和/或含有这些化合物的组合物的有效量来治疗这些障碍和症状的方法。
• Benzazepine derivative, process for producing the same, and use
  申请人：——

  公开号：US20040235822A1

  公开（公告）日：2004-11-25

  The present invention provides a novel benzazepine derivative represented by formula: 1 wherein, R 1 is a 5- or 6-membered aromatic ring, R 2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula —W 1 —X 2 —W 2 — (W 1 and W 2 are independently S(O) m1 (m1 is 0, 1, or 2), etc., and X 2 is an optionally substituted alkylene group etc.), a preparation method and use thereof.

  本发明提供了一种新型苯并氮杂环衍生物，其化学式表示为：1其中，R1为5-或6-成员芳香环，R2为低碳基，Y为可选取代的亚胺基，环A和环B分别为可选取代的芳香环，W为式—W1—X2—W2—（其中W1和W2分别为独立的S(O)m1（m1为0、1或2）等，X2为可选取代的烷基等），以及其制备方法和用途。
• Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
  申请人：Kamenecka M. Theodore

  公开号：US20070027321A1

  公开（公告）日：2007-02-01

  The present invention is directed to novel bipyridyl amine and ether compounds such as those of Formula (I): (I) (where R?1#191, R?2#191, R?3#191, X and Y are as defined herein) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel bipyridyl amine and/or ether compounds and/or compositions containing these compounds.

  本发明涉及新型的联吡啶胺和醚化合物，例如公式(I)中的化合物：(I) (其中R?1#191，R?2#191，R?3#191，X和Y如本文所定义)，这些化合物是mGluR5调节剂，可用于治疗或预防涉及mGluR5的疾病和病况，包括但不限于精神和情绪障碍，如精神分裂症、焦虑、抑郁、双相障碍和惊恐，以及治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍，如倒班工作引起的睡眠障碍和时差反应、药物成瘾、药物滥用、戒断综合征、肥胖症和其他疾病。本发明还涉及包含这些化合物的药物组合物。本发明还提供了通过给予这些新型联吡啶胺和/或醚化合物和/或含有这些化合物的组合物的有效量来治疗这些障碍和病况的方法。
• Triazole Compounds as Lipoxygenase Inhibitors
  申请人：Pelcman Benjamin

  公开号：US20090186918A1

  公开（公告）日：2009-07-23

  There is provided compounds of formula (I) wherein W is an optionally substituted aryl or heteroaryl group, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

  提供了化合物的公式(I)，其中W是可选取代的芳基或杂环芳基基团，以及其药学上可接受的盐。这些化合物在治疗需要抑制脂氧合酶(例如15-脂氧合酶)活性的疾病中非常有用，特别是在治疗炎症方面。